BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7809019)

  • 1. Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats.
    Tomita H; Miyasaka K; Jimi A; Mishima Y; Funakoshi A
    Pancreas; 1994 Sep; 9(5):638-45. PubMed ID: 7809019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
    Nakano S; Kihara Y; Otsuki M
    Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the CCK receptor antagonist CR 1409 on bile reflux pancreatitis in the opossum.
    Larsen F; Schlarman D; Andrus CC; Kaminski DL
    Pancreas; 1991 May; 6(3):291-7. PubMed ID: 1713673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
    Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in gene expression of pancreatitis-associated protein and pancreatic secretory trypsin inhibitors in experimental pancreatitis produced by pancreatic duct occlusion in rats: comparison with gene expression of cholecystokinin and secretin.
    Funakoshi A; Miyasaka K; Jimi A; Nakamura E; Teraoka H
    Pancreas; 1995 Aug; 11(2):147-53. PubMed ID: 7479671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cholecystokinin-A (CCK-A) receptor in pancreatic regeneration after pancreatic duct occlusion: a study in rats lacking CCK-A receptor gene expression.
    Miyasaka K; Ohta M; Tateishi K; Jimi A; Funakoshi A
    Pancreas; 1998 Mar; 16(2):114-23. PubMed ID: 9510132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
    Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T
    Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats.
    Miyasaka K; Funakoshi A; Jimi A; Nakamura R; Matsumoto M; Kitani K
    Dig Dis Sci; 1992 Mar; 37(3):369-77. PubMed ID: 1735360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early development of experimental biliary pancreatitis and its amelioration by CCK-receptor blockade.
    Niederau C; Borchard F; Lüthen R; Niederau M
    Hepatogastroenterology; 1996; 43(12):1442-53. PubMed ID: 8975946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
    Otsuki M; Nakano S; Tachibana I
    Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of cholecystokinin receptor antagonist loxiglumide on rat exocrine pancreas.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1994 Jul; 9(4):425-33. PubMed ID: 7937691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
    Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
    Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.
    Imoto I; Yamamoto M; Jia DM; Otsuki M
    Int J Pancreatol; 1997 Dec; 22(3):177-85. PubMed ID: 9444548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
    Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
    Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
    Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats.
    Song W; Yamaguchi H; Nakano I; Kimura T; Nawata H
    Fukuoka Igaku Zasshi; 1996 Jan; 87(1):14-22. PubMed ID: 8820983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
    Jia D; Yamamoto M; Otsuki M
    World J Gastroenterol; 2015 Jul; 21(25):7742-53. PubMed ID: 26167074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of CR1505, a CCK antagonist, on pancreatic growth in hamsters].
    Tasi Y; Baba N; Nishimura I; Manabe T; Tobe T
    Nihon Shokakibyo Gakkai Zasshi; 1991 Apr; 88(4):1097-104. PubMed ID: 1857003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR-1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA.
    Sazaki N; Miyasaka K; Matsumoto M; Funakoshi A
    J Gastroenterol; 1995 Oct; 30(5):599-606. PubMed ID: 8574331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.